DYX116

Primary objectives 1) To evaluate the safety and tolerability of DYX116 after a single subcutaneous injection in healthy/overweight adults. 2) To evaluate the safety and tolerability of DYX116 after multiple subcutaneous injections in overweight/obese adults. Secondary objectives 1) To evaluate the pharmacokinetic/pharmacodynamic characteristics of DYX116 after single or multiple subcutaneous injections. 2) To evaluate the effect of subcutaneous injection of DYX116 on the QTc interval in healthy/overweight/obese adults. 3) To evaluate the immunogenicity of DYX116 after subcutaneous injection in healthy/overweight/obese adults.